Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

A new study found a link between GLP-1s and a higher risk of neovascular age-related macular degeneration, an eye disease ...

Advert Previous studies linked the drug to a rare eye condition known as non-arteritic anterior ischemic optic neuropathy ...

Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide.

An Israeli study found patients taking Ozempic or similar weight-loss shots were twice as likely to suffer from a serious degenerative eye disease compared ... to a higher risk of kidney cancer ...

Semaglutide medications like Ozempic and Wegovy have shown proven results for managing conditions like type 2 diabetes and obesity. Also known as GLP-1 agonists, these drugs work by mimicking a ...

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

A European health authority has found that medications containing semaglutide—such as Ozempic, Wegovy, and Rybelsus—can ...

The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...